Wall Street analysts forecast that GW Pharmaceuticals PLC (NASDAQ:GWPH) will report earnings per share of ($1.39) for the current quarter, according to Zacks. Two analysts have made estimates for GW Pharmaceuticals PLC’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($2.12). GW Pharmaceuticals PLC reported earnings per share of ($0.89) in the same quarter last year, which suggests a negative year over year growth rate of 56.2%. The company is expected to announce its next earnings report on Monday, December 4th.

According to Zacks, analysts expect that GW Pharmaceuticals PLC will report full-year earnings of ($5.99) per share for the current year, with EPS estimates ranging from ($6.66) to ($5.04). For the next fiscal year, analysts expect that the firm will post earnings of ($6.43) per share, with EPS estimates ranging from ($6.96) to ($6.13). Zacks’ EPS averages are an average based on a survey of analysts that cover GW Pharmaceuticals PLC.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.73) by $0.34. The firm had revenue of $3.14 million during the quarter, compared to analyst estimates of $2.10 million. GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. During the same period last year, the company posted ($0.05) EPS.

A number of analysts have recently commented on GWPH shares. BidaskClub raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Zacks Investment Research raised GW Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $119.00 price objective on the stock in a research note on Monday, July 17th. Maxim Group set a $135.00 price objective on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Thursday, June 8th. Leerink Swann reissued an “outperform” rating and issued a $160.00 price objective (down previously from $162.00) on shares of GW Pharmaceuticals PLC in a research note on Thursday, August 10th. Finally, ValuEngine raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. GW Pharmaceuticals PLC presently has an average rating of “Buy” and an average price target of $148.55.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Alliancebernstein L.P. grew its holdings in shares of GW Pharmaceuticals PLC by 4.6% in the 1st quarter. Alliancebernstein L.P. now owns 286,475 shares of the biopharmaceutical company’s stock worth $34,646,000 after acquiring an additional 12,519 shares during the last quarter. Blair William & Co. IL acquired a new position in shares of GW Pharmaceuticals PLC in the 1st quarter worth $207,000. Victory Capital Management Inc. grew its holdings in shares of GW Pharmaceuticals PLC by 10.4% in the 1st quarter. Victory Capital Management Inc. now owns 283,025 shares of the biopharmaceutical company’s stock worth $34,229,000 after acquiring an additional 26,638 shares during the last quarter. Eqis Capital Management Inc. grew its holdings in shares of GW Pharmaceuticals PLC by 23.3% in the 2nd quarter. Eqis Capital Management Inc. now owns 2,899 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 547 shares during the last quarter. Finally, HighTower Advisors LLC grew its holdings in shares of GW Pharmaceuticals PLC by 10.3% in the 1st quarter. HighTower Advisors LLC now owns 2,044 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 191 shares during the last quarter. Institutional investors and hedge funds own 75.07% of the company’s stock.

WARNING: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/10/zacks-brokerages-expect-gw-pharmaceuticals-plc-gwph-will-announce-earnings-of-1-39-per-share.html.

GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down 0.87% during mid-day trading on Friday, reaching $107.58. The company’s stock had a trading volume of 186,042 shares. The firm has a 50 day moving average price of $107.08 and a 200-day moving average price of $110.76. GW Pharmaceuticals PLC has a 1-year low of $92.65 and a 1-year high of $137.88. The company’s market capitalization is $2.72 billion.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.